Klaus Bendtzen

Q: What Schools Are Affiliated With Klaus Bendtzen

Klaus Bendtzen is affiliated with the following schools: University of Catania, University of Milan, University of Messina, University of Copenhagen

Klaus Bendtzen's AcademicInfluence.com Rankings

Klaus Bendtzen

Biology

#6281

World Rank

#8959

Historical Rank

Immunology

#318

World Rank

#331

Historical Rank

biology Degrees

Download Badge

Biology

Klaus Bendtzen's Degrees

PhD Medical Science University of Copenhagen
Doctorate Medicine University of Copenhagen

Why Is Klaus Bendtzen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Klaus Bendtzen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. (1986) (580)
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. (1999) (476)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. (2006) (427)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial (2013) (416)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis (2008) (397)
Prognostic laboratory markers of joint damage in rheumatoid arthritis (2004) (396)
Interleukin-1 beta-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. (1991) (357)
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis (2003) (354)
Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. (1994) (321)
Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. (1987) (307)
Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. (1988) (262)
Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management (2010) (257)
Autoantibodies to cytokines--friends or foes? (1990) (221)
Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration (2000) (214)
Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. (2007) (211)
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy (2005) (198)
1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. (1992) (195)
Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans (1985) (195)
Immunohistological detection of interleukin 1‐like molecules and tumour necrosis factor in human epidermis before and after UVB‐irradiation in vivo (1988) (191)
T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis (2008) (187)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease (2011) (175)
Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case–control study nested in a cohort of Norwegian blood donors (2007) (166)
Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease (2002) (160)
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies (2009) (156)
Association between HLA‐DR2 and Production of Tumour Necrosis Factor α and Interleukin 1 by Mononuclear Cells Activated by Lipopolysaccharide (1988) (155)
Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease (2008) (155)
Mediators of immunity: lymphokines and monokines. (1980) (155)
Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis (1993) (155)
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease (2011) (148)
Periodontal and hematological characteristics associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. (2006) (147)
Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. (1990) (142)
Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans (2006) (141)
Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial (2014) (129)
Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. (1998) (128)
Binding of cytokines to pharmaceutically prepared human immunoglobulin. (1993) (128)
Modulation of Natural Killer Cell Activity in Peripheral Blood by Physical Exercise (1988) (128)
High-avidity autoantibodies to cytokines. (1998) (123)
Marginal periodontitis and cytokines: a review of the literature. (1993) (123)
Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. (1991) (122)
Interleukin 6 primes human neutrophil and monocyte oxidative burst response. (1989) (122)
Cytokines in sputum and serum from patients with cystic fibrosis and chronic pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. (1993) (121)
Auto‐Antibodies to Tumour Necrosis Factor a in Healthy Humans and Patients with Inflammatory Diseases and Gram‐Negative Bacterial Infections (1989) (117)
Anti‐Interleukin‐6 Antibodies in Normal Human Serum (1991) (115)
Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. (1986) (115)
Validity of histopathological grading of articular cartilage from osteoarthritic knee joints (1999) (114)
Interferons and interferon (IFN)‐inducible protein 10 during highly active anti‐retroviral therapy (HAART)—possible immunosuppressive role of IFN‐α in HIV infection (2000) (112)
Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease (2013) (112)
Studies on the mechanisms causing inhibition of insulin secretion in rat pancreatic islets exposed to human interleukin-1 beta indicate a perturbation in the mitochondrial function. (1989) (109)
Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases. (1989) (109)
Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. (2000) (107)
1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. (1996) (106)
Clinical implications of variations in anti‐infliximab antibody levels in patients with inflammatory bowel disease (2012) (105)
Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing Type I diabetes (2001) (103)
Effect of physical exercise on in vitro production of interleukin 1, interleukin 6, tumour necrosis factor-α, interleukin 2 and interferon-γ (1991) (103)
Cytokine profiles in peripheral blood and whole blood cell cultures associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. (2005) (101)
Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. (1997) (101)
Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. (2011) (96)
Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD (2014) (95)
Increased serum levels of interleukin-18 in patients with multiple sclerosis (2001) (94)
Murine concanavalin A–induced hepatitis is prevented by interleukin 12 (IL‐12) antibody and exacerbated by exogenous IL‐12 through an interferon‐γ–dependent mechanism (2000) (93)
Cytokine expression in labial salivary glands from patients with primary Sjögren's syndrome. (1992) (92)
Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies (2020) (90)
Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies (2016) (90)
Histologic/histochemical grading system for osteoarthritic articular cartilage: reproducibility and validity. (1997) (88)
Cytokines and natural regulators of cytokines. (1994) (87)
1,25-dihydroxyvitamin D3 selectively reduces interleukin-2 levels and proliferation of human T cell lines in vitro. (1993) (87)
IgG Autoantibodies against Interleukin 1α in Sera of Normal Individuals (1989) (86)
Interleukin-13 prevents autoimmune diabetes in NOD mice. (1999) (86)
Islet Cytotoxicity of Interleukin 1: Influence of Culture Conditions and Islet Donor Characteristics (1987) (86)
mTOR as a multifunctional therapeutic target in HIV infection. (2011) (86)
High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. (1995) (85)
Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. (2009) (85)
Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. (2004) (85)
Mechanisms of Pancreatic Islet Cell Destruction Dose‐Dependent Cytotoxic Effect of Soluble Blood Mononuclear Cell Mediators on Isolated Islets of Langerhans (1986) (83)
Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab (2015) (83)
Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. (1993) (82)
Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay. (1991) (81)
Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. (1998) (80)
Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. (1994) (79)
Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D3. Differential effects on CD45RA+ and CD45R0+ cells. (1992) (78)
Prevention of endotoxin‐induced lethality in neonatal mice by interleukin‐13 (1997) (78)
Polymorphisms within the IL-1 gene cluster: effects on cytokine profiles in peripheral blood and whole blood cell cultures of patients with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. (2007) (76)
Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases (1988) (76)
Tumour necrosis factor alpha during human pregnancy and labour: maternal plasma and amniotic fluid concentrations and release from intrauterine tissues. (1994) (76)
Potential use of rapamycin in HIV infection. (2010) (74)
Serum Cardiac Troponin I in Acute Stroke Is Related to Serum Cortisol and TNF-α (2004) (72)
The role of monocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. (1991) (71)
Detection of Tumour Necrosis Factor from Lipopolysaccharide‐Stimulated Human Mononuclear Cells by Enzyme‐Linked Immunosorbent Assay and Cytotoxicity Bioassay (1988) (69)
Bioactive and inactive forms of tumor necrosis factor-alpha in spinal fluid from patients with meningitis. (1991) (69)
1 alpha,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. (1988) (68)
High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. (1993) (68)
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. (2012) (68)
Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS (2006) (68)
Human anti-interleukin 1α antibodies (1991) (68)
Expression of α and β subunits of the integrin superfamily in articular cartilage from macroscopically normal and osteoarthritic human femoral heads (1998) (67)
Increased plasma levels of IL-6 in bacteremic periodontis patients after scaling. (2006) (65)
Autoantibodies against interleukin 1α in rheumatoid arthritis: association with long term radiographic outcome (2002) (64)
Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Time and temperature dependent spontaneous release in vitro demands standardized sample processing. (1993) (64)
Systemic inflammatory responses during laparoscopic and open inguinal hernia repair: a randomised prospective study. (2000) (64)
Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1 (2009) (64)
Elucidation of IL-1/TGF-beta interactions in mouse chondrocyte cell line by genome-wide gene expression. (2005) (63)
Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor‐α and interferon‐γ, and has potential in the treatment of arthritis (2003) (62)
Cytokines and autoantibodies to cytokines (1995) (62)
Distribution and Characterization of Autoantibodies to Interleukin 1α in Normal Human Sera (1990) (62)
Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP (2009) (61)
Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection (2015) (61)
Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. (2013) (61)
Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. (2015) (61)
Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria (1994) (60)
Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? (2011) (59)
Possible role of IL-1, TNF-alpha, and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Thyroid Cell Group. (1989) (59)
HIV‐protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO‐hybridized derivatives? (2017) (58)
Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine. (2012) (58)
Infections and treatment of patients with rheumatic diseases. (2008) (58)
In vitro immunomodulatory effects of pentoxifylline. (1993) (58)
Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. (1999) (56)
Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease (2013) (55)
Cytokines in Plasma and Ultrafiltrate during Continuous Arteriovenous Haemofiltration (1993) (55)
Enhancement of human adaptive immune responses by administration of a high-molecular-weight polysaccharide extract from the cyanobacterium Arthrospira platensis. (2008) (55)
Anti-IFN BAb and NAb antibodies (2003) (54)
Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. (2004) (54)
Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin‐6 signal transducer gp130 1 (1997) (54)
Inhibitor of Interleukin 1 in Normal Human Urine (1988) (54)
Eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Detection by enzyme-linked immunosorbent assay and purification from normal human urine. (1991) (52)
Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. (1997) (52)
Differential release of interleukin-6 from human gestational tissues in association with labour and in vitro endotoxin treatment. (1996) (51)
Modulation of human neutrophil and monocyte chemotaxis and superoxide responses by recombinant TNF-alpha and GM-CSF. (1988) (51)
Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. (2014) (50)
Mechanism of Action of Cyclosporin A (1984) (49)
Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. (1990) (49)
Influence of tumour necrosis factor-alpha, tumour necrosis factor-beta and interferon-gamma, separately and added together with interleukin-1 beta, on the function of cultured human thyroid cells. (1994) (49)
The Atherogenic Bacterium Porphyromonas gingivalis Evades Circulating Phagocytes by Adhering to Erythrocytes (2011) (48)
Effects of human anti-IL-1 alpha autoantibodies on receptor binding and biological activities of IL-1. (1992) (48)
CYCLOSPORIN FOR POLYMYOSITIS (1984) (48)
Differential Sensitivity to β-Cell Secretagogues in Cultured Rat Pancreatic Islets Exposed to Human Interleukin-1β* (1989) (48)
Deteriorating ischaemic stroke cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke (2002) (47)
Metabolism and β-cell function of rat pancreatic islets exposed to human interleukin-1β in the presence of a high glucose concentration (1990) (47)
Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. (1997) (47)
Short exposure of rat pancreatic islets to interleukin-1 beta induces a sustained but reversible impairment in beta-cell function: influence of protease activation, gene transcription, and protein synthesis. (1991) (46)
Cell saver for on-pump coronary operations reduces systemic inflammatory markers: a randomized trial. (2010) (46)
The cytokine network in the pathogenesis of major depressive disorder. Close to translation? (2020) (46)
The inflammatory cytokine response after autotransfusion of shed mediastinal blood (1998) (45)
Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. (2000) (45)
Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosis (2006) (45)
Bacterial-stimulated cytokine production of peripheral mononuclear cells from patients of various periodontitis categories. (1995) (45)
Interleukin 6: a functional and structural in vitro modulator of beta-cells from islets of Langerhans. (1990) (44)
Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors (1995) (44)
Epidermal tumour necrosis factor α and interleukin 6‐like activities in AIDS‐related Kaposi's sarcoma (1989) (43)
High levels of neutralizing IL‐6 autoantibodies in 0.1% of apparently healthy blood donors (2004) (42)
[Chronic fatigue syndrome--a controlled cross-sectional study]. (1994) (41)
Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus (2014) (41)
Hypomethylating Agent 5‐Aza‐2′‐deoxycytidine (DAC) Ameliorates Multiple Sclerosis in Mouse Models (2014) (41)
Effect of physical exercise on in vitro production of interleukin 1, interleukin 6, tumour necrosis factor-alpha, interleukin 2 and interferon-gamma. (1991) (41)
Expression of interleukin-6-like molecules and tumour necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC 903). (1989) (40)
Influence of Phthalates on Cytokine Production in Monocytes and Macrophages: A Systematic Review of Experimental Trials (2015) (40)
IL-2 induces beta2-integrin adhesion via a wortmannin/LY294002-sensitive, rapamycin-resistant pathway. Phosphorylation of a 125-kilodalton protein correlates with induction of adhesion, but not mitogenesis. (1996) (40)
Interleukin‐1 affects the function of cultured human thyroid cells (1988) (40)
TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. (2004) (40)
Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease (2012) (40)
Beta-galactosylceramide increases and sulfatide decreases cytokine and chemokine production in whole blood cells. (2004) (39)
An interleukin-1 receptor antagonist protein protects insulin-producing Beta cells against suppressive effects of interleukin-1β (1991) (39)
Increased In Vivo Antibody Activity Against Interferon α, Interleukin-1α, and Interleukin-6 After High-Dose Ig Therapy (1997) (39)
The effect of interleukin-1 on the thyroid gland. (1993) (39)
Increased plasma levels of soluble IL‐2R are associated with severe Plasmodium falciparum malaria (1994) (39)
Influence of Phthalates on in vitro Innate and Adaptive Immune Responses (2015) (39)
Production of interleukin (IL)‐5 and IL‐10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self‐antigen, thyroglobulin, in health and autoimmune thyroid disease (2006) (38)
Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist (1997) (38)
Nicotinamide decreases nitric oxide production and partially protects human pancreatic islets against the suppressive effects of combinations of cytokines. (1994) (38)
Indirect assessment of eosinophiluria in urinary schistosomiasis using eosinophil cationic protein (ECP) and eosinophil protein X (EPX). (1993) (38)
Blood cell gene expression profiling in subjects with aggressive periodontitis and chronic arthritis. (2008) (38)
CD44 expression is up‐regulated in the deep zone of osteoarthritic cartilage from human femoral heads (1997) (38)
Decreased cell replication and polyamine content in insulin-producing cells after exposure to human interleukin 1 beta. (1989) (38)
The production of heterologous antibodies to the human lymphakine: leukocyte migration inhibitory factor (LIF). (1977) (37)
Essential pathogenic role of endogenous IL‐18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL‐18‐binding protein: Fc construct (2003) (37)
Biological Properties of Interleukins (1983) (37)
Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. (2011) (37)
IL‐6 GENE POLYMORPHISM IN RHEUMATOID ARTHRITIS, PAUCIARTICULAR JUVENILE RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, AND IN HEALTHY DANES (1989) (37)
Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis (2006) (37)
Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis? (2007) (37)
Cytokines in inflammatory bowel disease. (1992) (36)
Gasotransmitters and the immune system: Mode of action and novel therapeutic targets (2018) (36)
Massive parallel gene expression profiling of RINm5F pancreatic islet β‐cells stimulated with interleukin‐1β (2000) (36)
Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events (2017) (36)
Thyrocyte-interleukin-1 interactions. (2000) (35)
AN IN VITRO ASSAY OF LEUKOCYTE MIGRATION INHIBITORY ACTIVITY FROM HUMAN LYMPHOCYTES STIMULATED WITH CONCANAVALIN A (1975) (35)
Sex‐ and age‐dependency of IgG auto‐antibodies against IL‐1α in healthy humans (1994) (34)
Proliferation induced by Plasmodium falciparum antigen and interleukin-2 production by lymphocytes isolated from malaria-immune individuals (1986) (34)
Prevention of Spontaneous Autoimmune Diabetes in NOD Mice by Transferring in VitroAntigen-Pulsed Syngeneic Dendritic Cells. (2000) (34)
B-cell depletion with rituximab in the treatment of autoimmune diseases (2007) (34)
Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. (1995) (33)
Pathogenic contribution of the Macrophage migration inhibitory factor family to major depressive disorder and emerging tailored therapeutic approaches. (2019) (33)
Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in chronic inflammatory bowel disease. (1993) (33)
Abnormal vitamin D3 metabolism in patients with primary Sjögren's syndrome. (1990) (33)
Effects of 1,25-dihydroxyvitamin D3 and the analogues MC903 and KH1060 on interleukin-1β-induced inhibition of rat pancreatic islet β-cell function in vitro (1994) (32)
Labour-associated increase in interleukin-1 alpha release in vitro by human gestational tissues. (1996) (32)
In vitro cytokine production and phenotype expression by blood mononuclear cellsfrom umbilical cords, children and adults (1996) (32)
Interleukin-1 beta increases the biosynthesis of the heat shock protein hsp70 and selectively decreases the biosynthesis of five proteins in rat pancreatic islets. (1991) (32)
LONG‐TERM FOLLOW‐UP OF KIDNEY TRANSPLANT PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: DURATION OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER‐INDUCED OPERATIONAL GRAFT TOLERANCE, INTERLEUKIN‐18 COURSE, AND RESULTS OF RETRANSPLANTATION (2003) (32)
Anti-diabetogenic effect of fusidic acid in diabetes prone BB rats. (1992) (31)
Keratinocyte-expression of interleukin-6 but not of tumour necrosis factor-alpha is increased in the allergic and the irritant patch test reaction. (1991) (31)
Protection from concanavalin A (Con A)‐induced T cell‐dependent hepatic lesions and modulation of cytokine release in mice by sodium fusidate (1997) (31)
Genetic Variants in Toll-Like Receptors Are Not Associated with Rheumatoid Arthritis Susceptibility or Anti-Tumour Necrosis Factor Treatment Outcome (2010) (31)
The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for the development of human Th1 cells. (1999) (31)
Immunocytochemical localisation of interleukin-1 alpha and interleukin-6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. (1995) (31)
Specific and Strain‐Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents (2010) (31)
Methotrexate induces poly(ADP‐ribose) polymerase‐dependent, caspase 3‐independent apoptosis in subsets of proliferating CD4+ T cells (2007) (30)
Effect of methylprednisolone on the cytokine response in patients undergoing lung surgery (1993) (30)
Pronounced Inflammatory Response to Endotoxaemia during Nighttime: A Randomised Cross-Over Trial (2014) (30)
Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients (2010) (30)
INHIBITION OF HUMAN LEUKOCYTE MIGRATION INHIBITORY FACTOR (LIF) BY α‐L‐FUCOSE (1975) (30)
Recombinant Interleukin α and ß Prime Human Monocyte Superoxide Production but Have no Effect on Chemotaxis and Oxidative Burst Response of Neutrophils (1988) (30)
Human Leukocyte Migration Inhibitory Factor (LIF) (1977) (30)
Production of IL-1beta, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. (1999) (29)
MHC class II molecules regulate growth in human T cells. (1994) (29)
Human Leucocyte Migration Inhibition (1976) (29)
Detection of autoantibodies to cytokines (2000) (29)
Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. (2003) (29)
Interleukin-6 in the epidermis of patients with psoriasis before and during PUVA treatment. (1989) (29)
Elevated plasma interleukin 6: a biochemical marker of human preterm labour. (1993) (28)
Anti‐Interleukin‐6 Autoantibodies in Plasma are Associated with an Increased Frequency of Infections and Increased Mortality of Patients with Alcoholic Cirrhosis (1996) (28)
Inhibitory Effect of Cyclosporin A on Histamine Release from Human Leukocytes and Rat Mast Cells (1985) (28)
The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major. (1998) (27)
Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence (2015) (27)
Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy. (1991) (27)
Spironolactone induces apoptosis and inhibits NF-κB independent of the mineralocorticoid receptor (2006) (27)
Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction (2006) (27)
Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors. (2009) (27)
Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin (1992) (27)
Demonstration of circulating leukocytic pyrogen/interleukin-1 during fever. (1984) (27)
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis (2009) (26)
Interleukin‐6 and tumour necrosis factor alpha are expressed by keratinocytes but not by Langerhans cells (1991) (26)
Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study (2016) (26)
Serum‐induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN‐α in normal human sera (1992) (26)
Naturally Occurring Autoantibodies to Interleukin-1α, Interleukin-6, Interleukin-10, and Interferon-α (1994) (26)
Macrophage-derived cytokines in the follicular fluids of women with infertility due to immunological causes. Elevated levels of interleukin 6 and low levels of granulocyte-macrophage colony-stimulating factor. (1998) (26)
EBV-induced post-transplant lymphoproliferative disorder (PTLD). (1995) (26)
Down-regulation of monocyte functions by treatment of healthy adults with 1 alpha,25 dihydroxyvitamin D3. (1991) (26)
The influence of interleukin-1 on the function of in vitro cultured human thyroid cells in monolayers. (1987) (25)
Cytokine autoantibodies in rheumatoid arthritis. (1995) (25)
Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. (1989) (25)
Quantitative assessment of clinical disease status in primary Sjögren's syndrome. A cross-sectional study using a new classification model. (1997) (25)
Interleukin-6 autoantibodies: possible biological and clinical significance. (1995) (25)
Selective Modulation of the CD4 Molecular Complex by Pseudomonas aeruginosa Alkaline Protease and Elastase (1987) (25)
Multiplex Screening of 22 Single-Nucleotide Polymorphisms in 7 Toll-like Receptors: An Association Study in Rheumatoid Arthritis (2010) (24)
Cell‐mediated immune responses to soluble Plasmodium falciparum antigens in residents from an area of unstable malaria transmission in the Sudan (1990) (24)
Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production (2011) (24)
Influence of Protease on Inhibitory and Stimulatory Effects of Interleukin 1β on β-Cell Function (1991) (24)
Antigenicity and protein content of perilymph in acoustic neuroma patients. (1984) (24)
An interleukin-1 receptor antagonist protein protects insulin-producing beta cells against suppressive effects of interleukin-1 beta. (1991) (24)
Involvement of interleukin-1 genotypes in the association of coronary heart disease with periodontitis. (2008) (24)
Stimulation of the B9 hybridoma cell line by soluble interleukin-6 receptors. (1994) (24)
IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. (1989) (23)
Molecular cloning and expression of a novel Staphylococcus aureus antigen. (1997) (23)
Treatment of chronic endogenous uveitis with fusidic acid (1991) (23)
Biomolecular regulation of the IgE immune response (1992) (23)
Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes (2014) (23)
Differential binding of human interleukin‐1 (IL‐1) receptor antagonist to natural and recombinant soluble and cellular IL‐1 type I receptors (1995) (23)
Sulphatide and its precursor galactosylceramide influence the production of cytokines in human mononuclear cells (1996) (23)
Role of receptor binding and gene transcription for both the stimulatory and inhibitory effects of interleukin-1 in pancreatic beta-cells. (1992) (23)
Time Course and Clinical Implications of Development of Antibodies Against Adalimumab in Patients With Inflammatory Bowel Disease (2016) (23)
Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. (1994) (23)
Interleukin-1 receptors on human thyroid cells and on the rat thyroid cell line FRTL-5. (1991) (23)
Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? (2008) (23)
The effect of spironolactone on experimental periodontitis in rats. (2005) (22)
Liposomal delivery of antioxidant enzymes protects against hydrogen peroxide- but not interleukin-1 beta-induced inhibition of glucose metabolism in rat pancreatic islets. (1994) (22)
Human Leukocyte Migration Inhibitory Factor (LIF) (1977) (22)
Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation (2006) (22)
In vitro production of cytokines is influenced by sulfatide and its precursor galactosylceramide (1999) (22)
Expression of alpha and beta subunits of the integrin superfamily in articular cartilage from macroscopically normal and osteoarthritic human femoral heads. (1998) (22)
Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers (2015) (21)
Cytokine vaccination: neutralising IL-1α autoantibodies induced by immunisation with homologous IL-1α (2000) (21)
Production of human leukocyte migration inhibitory factor (LIF) by lymphocytes stimulated with phytohemagglutinin. I. Effect of various metabolic inhibitors. (1981) (21)
Tumour necrosis factor‐α (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis (2001) (21)
Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β (2009) (21)
Effect of fusidic acid on interleukin-1 (IL-1)- and IL-6-induced pancreatic beta-cell functions in rats. (1992) (21)
Cholesterol crystals enhance TLR2- and TLR4-mediated pro-inflammatory cytokine responses of monocytes to the proatherogenic oral bacterium Porphyromonas gingivalis (2017) (21)
Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock (1996) (21)
Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy. (1997) (21)
Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis (2004) (20)
Human Leucocyte Migration Inhibitory Factor (LIF) (1978) (20)
Immunosuppressive actions of gold salts. (1983) (20)
Production of interferon-gamma and interleukin-4 by human T cells recognizing Leishmania lipophosphoglycan-associated protein. (1993) (20)
Recombinant human tumour necrosis factor increases cytosolic free calcium in murine fibroblasts and stimulates inositol phosphate formation in L-M and arachidonic acid release in 3T3 cells. (1990) (20)
Role of Zn2+ and Other Divalent Metal Ions in Human Lymphokine Production in Vitro (1982) (20)
Immunolocalisation of Interleukin-4 and Interleukin-4 Receptor in Placenta and Fetal Membranes in Association with Pre-Term Labour and Pre-Eclampsia (1998) (20)
Comparison of mRNA contents of interleukin-1Β and nitric oxide synthase in pancreatic islets isolated from female and male nonobese diabetic mice (1995) (20)
The Effects of Interleukin-1β (IL-1β) on Human Thyrocyte Functions Are Counteracted by the IL-1 Receptor Antagonist. (1997) (20)
GM-CSF autoantibodies in pulmonary alveolar proteinosis. (2007) (19)
Cytokines and soluble IL‐4 in patients with acute optic neuritis and multiple sclerosis (1997) (19)
Expression of an insulin/interleukin-1 receptor antagonist hybrid gene in insulin-producing cell lines (HIT-T15 and NIT-1) confers resistance against interleukin-1-induced nitric oxide production. (1995) (19)
Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial (2014) (19)
Human Leukocyte Migration Inhibitory Factor (LIF) (1977) (19)
Infusion of hypertonic saline (7.5% NaCl) causes minor immunological changes in normovolaemic women (2004) (19)
Autoantibodies to cytokines in IVIG. (1993) (18)
Differential effects of interleukin 1α and 1β on cultured human and rat thyroid epithelial cells (1990) (18)
Influence of interleukin 6 on the function of secondary cultures of human thyrocytes. (1991) (18)
Critical review: assessment of interferon-β immunogenicity in multiple sclerosis. (2010) (18)
Soluble tumor necrosis factor (TNF) receptors conserve TNF bioactivity in meningitis patient spinal fluid. (1996) (18)
Soluble products of inflammatory reactions are not induced in children with asymptomatic Plasmodium falciparum infections (1996) (18)
Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors. (1996) (18)
Increased circulating levels of interleukin-6 in HIV-seropositive subjects. (1996) (18)
Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease (2016) (18)
Involvement of Interleukin-1 Genotypes in the Association of Coronary Heart Disease With Periodontitis (2008) (17)
Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes. (1987) (17)
Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. (2012) (17)
Staphylococcal enterotoxin-A directly stimulates signal transduction and interferon-gamma production in psoriatic T-cell lines. (1998) (17)
Cultures of Human Colonic Epithelial Cells Isolated from Endoscopical Biopsies from Patients with Inflammatory Bowel Disease. Effect of IFNγ, TNFα and IL-1β on Viability, Butyrate Oxidation and IL-8 Secretion (2000) (17)
Effects of Prolonged Exposure in Vitro to Interferon-γ and Tumour Necrosis Factor-α on Nitric Oxide and Insulin Production of Rat Pancreatic Islets (1995) (17)
Effect of cyclosporin A (CyA) on the immune response. CyA competitively inhibits the function of monocyte/macrophage-derived T-lymphocyte-activating factor(s). (1982) (17)
Effects of Growth Factors on Cytokine Production in Serum‐Free Cultures of Human Thymic Epithelial Cells (1993) (17)
Epidermal tumour necrosis factor alpha and interleukin 6-like activities in AIDS-related Kaposi's sarcoma. An immunohistological study. (1989) (17)
Some physicochemical properties of human leucocyte migration inhibitory factor (LIF). (1976) (16)
Differential Role of Zn2+ in Antigen‐ and Mitogen‐induced Lymphokine Production (1980) (16)
Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study (2015) (16)
Serum levels of C-reactive protein in adolescents with periodontitis. (2011) (16)
The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. (2008) (16)
Prevention of murine experimental autoimmune orchitis by recombinant human interleukin-6. (2002) (16)
Proinflammatory effects of exogenously administered IL-10 in experimental autoimmune orchitis. (2003) (16)
Early prophylaxis with recombinant human interleukin-11 prevents spontaneous diabetes in NOD mice. (1999) (16)
Native inhibitors (autoantibodies) of IL-1α and TNF (1989) (15)
Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. (2007) (15)
Leucocyte migration inhibitory activity of concanavalin-A-stimulated human lymphocytes. Modification by dipyridamole, lysine-acetylsalicylate and heparin. (2009) (15)
Tumor necrosis factor-alpha increases myocardial microvascular transport in vivo. (1994) (15)
Neutralizing antibodies to interferon (IFN) α-2a and IFN β-1a or IFN β-1b in MS are not cross-reactive (2000) (15)
Functional characteristics of synovial fluid and blood mononuclear cells in rheumatoid arthritis and traumatic synovitis. (1982) (15)
Human Leukocyte Migration Inhibitory Factor (LIF) (1977) (15)
Human anti-interleukin 1 alpha antibodies. (1991) (15)
The peri-operative cytokine response in infants and young children following major surgery. (1998) (15)
[Spironolactone inhibits production of proinflammatory cytokines, including tumor necrosis factor-alpha and interferon-gamma and has potential effect in the treatment of arthritis]. (2004) (15)
1,25-Dihydroxyvitamin D3-mediated suppression of T lymphocyte functions and failure of T cell-activating cytokines to restore proliferation. (1992) (15)
Effects of natural and recombinant interleukin-1 alpha and -beta on cytosolic free calcium in human and murine fibroblasts. (1988) (15)
Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro (1995) (14)
Immunoregulation by Naturally Occurring and Disease-Associated Autoantibodies (2012) (14)
Induction of antigen-specific lymphocyte unresponsiveness in vitro: possible role of divalent cations and defective function of human T-cell-activating factor (TAF). (1982) (14)
Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements [letter] (1995) (14)
Decreased interleukin-2 responses to Fusobacterium nucleatum and Porphyromonas gingivalis in generalized aggressive periodontitis. (2009) (14)
Nitric Oxide Production is not involved in the Effects of Interleukin-1β on CAMP, Thyroglobulin and Interleukin-6 in TSH-Stimulated Human Thyroid Cells (1994) (14)
Production of leucocyte migration inhibitory factor (LIF) in infectious mononucleosis. Spontaneous release and lack of response to concanavalin A. (1978) (14)
Knocking out IL‐6 by vaccination (2004) (14)
In Vitro Cytokine Responses to Periodontal Pathogens: Generalized Aggressive Periodontitis is Associated with Increased IL‐6 Response to Porphyromonas gingivalis (2010) (14)
Plasma cytokines in acute stroke. (2002) (14)
Variation in NOD2 Augments Th2- and Th17 Responses to Myelin Basic Protein in Multiple Sclerosis (2011) (14)
Ciclosporin (Cyclosporin A): Prototype of a New Generation of Immunosuppressive Drugs (1984) (14)
[Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis]. (2004) (14)
The effects of interleukin-1beta (IL-1beta) on human thyrocyte functions are counteracted by the IL-1 receptor antagonist. (1997) (14)
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis (2009) (14)
Cytokines in autoimmunity. (1987) (14)
Specific autoantibodies directed against interferon-alpha in pharmaceutically prepared human immunoglobulin preparations. (1994) (14)
Sodium fusidate ameliorates the course of diabetes induced in mice by multiple low doses of streptozotocin. (2000) (14)
In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. (2008) (14)
Biomolecular regulation of the IgE immune response III. Cytokine profiles in atopic dermatitis, inhalant allergy and non-allergic donors. (1996) (13)
Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro (2016) (13)
Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta (2010) (13)
Letter: persistence of anti‐infliximab antibodies after discontinuation of infliximab in patients with IBD (2012) (13)
CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis (2005) (13)
Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. (2000) (13)
Sodium fusidate in Guillain-Barré syndrome: a case report (1998) (13)
Effects of Immunomodulators on Ecto‐5′‐Nucleotidase Activity on Blood Mononuclear Cells In Vitro (1992) (13)
Thl‐Like Human T‐Cell Clones Recognizing Leishmania gp63 Inhibit Leishmania major in Human Macrophages (1994) (13)
Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis (2004) (13)
A Role for Cyclosporin A in the Treatment of Insulin‐dependent Diabetes Mellitus? (1985) (13)
Immunochemical and Biological Reactivity of Human Anti‐Lipopolysaccharide IgG Obtained by Screening of Blood Donors (1989) (13)
Seasonal Variations in T-Lymphocyte Response to Grass Pollen Allergens from Pollen-Allergic Patients and Healthy Controls (1998) (13)
Cytokine-induced impairment of short-chain fatty acid oxidation and viability in human colonic epithelial cells. (2000) (13)
Prevention of carrageenan-induced pleurisy in mice by anti-CD30 ligand monoclonal antibody. (2004) (13)
Involvement of monokines in antigen- and lectin-induced human lymphokine production. (2009) (12)
An Imidazoline Compound Completely Counteracts Interleukin-1β toxic Effects to Rat Pancreatic Islet β Cells (2002) (12)
Specific cellular immunity in acoustic neuroma patients (1983) (12)
Tumor necrosis factor-β in human pregnancy and labor☆ (1997) (12)
Fusidic acid and insulin-dependent diabetes mellitus. (1996) (12)
MspI polymorphism in the human interleukin 6 (IL 6) gene. (1989) (12)
Recombinant human tumour necrosis factor is not inhibitory to Plasmodium falciparum in vitro. (1988) (11)
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (2008) (11)
Production of leukocyte migration inhibitory factor (LIF) in human lymphocyte subsets exposed to polyclonal activators. (1984) (11)
Effect of methylprednisolone on the cytokine response in patients undergoing lung surgery. (1992) (11)
Self-Reactive CD4+ T Cells and B Cells in the Blood in Health and Autoimmune Disease: Increased Frequency of Thyroglobulin-Reactive Cells in Graves’ Disease (2006) (11)
Adhesion molecules in inflammatory and neoplastic intestinal diseases. (1995) (11)
Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. I. T-cell-activating factor abrogates CyA- but not MP-induced suppression of antigen-induced lymphokine production. (1982) (11)
Massive parallel gene expression profiling of RINm5F pancreatic islet beta-cells stimulated with interleukin-1beta. (2000) (11)
Increased polymorphonuclear leukocyte cGMP levels induced by the human lympholine, leukocyte migration inhibitory factor (LIF). (1979) (10)
Metabolism and beta-cell function of rat pancreatic islets exposed to human interleukin-1 beta in the presence of a high glucose concentration. (1990) (10)
Influence of endotoxin on production of leucocyte migration inhibition factor. Part I. (1984) (10)
Effects of the immunomodulator, VGX‐1027, in endotoxin‐induced uveitis in Lewis rats (2008) (10)
Recombinant interleukin 1 alpha and beta prime human monocyte superoxide production but have no effect on chemotaxis and oxidative burst response of neutrophils. (1988) (10)
POSSIBLE CORRELATION OF TNFα‐PRODUCTION WITH ‐RFLP IN HUMANS (1989) (10)
Effects of 1,25-dihydroxyvitamin D3 and the analogues MC903 and KH1060 on interleukin-1 beta-induced inhibition of rat pancreatic islet beta-cell function in vitro. (1994) (10)
Decreased Short-Term Production of Tumor Necrosis Factor-α and Interleukin-1β in Human Immunodeficiency Virus-Seropositive Subjects (1997) (10)
IFN-α Antibodies in Patients with Age-Related Macular Degeneration Treated with Recombinant Human IFN-α2a (2002) (10)
Pattern recognition receptor polymorphisms in early periodontitis. (2019) (10)
Biological assays for interleukin 1 detection (1991) (10)
Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1β and inhibited by growth hormone releasing hormone and somatostatin. (2011) (10)
Case Study: Immunogenicity of Anti-TNF Antibodies (2008) (9)
A standardized human T-lymphocyte proliferation assay for detecting soluble accessory factors from monocytes. I. Monocyte and monokine requirements. (2009) (9)
Immunocytochemical localisation of tumor necrosis factor alpha in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders. (1996) (9)
Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. (1996) (9)
Spironolactone induces apoptosis in human mononuclear cells. Association between apoptosis and cytokine suppression (2006) (9)
Gene expression profiling in autoimmune diseases: Chronic inflammation or disease specific patterns? (2007) (9)
IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: an in vitro phenomenon depending upon plastic adherence. (1995) (9)
Leukocyte migration inhibitory factor: a serine esterase released by stimulated human lymphocytes. Kinetic analysis and inhibition by cyclic GMP. (1979) (9)
Differential sensitivity to beta-cell secretagogues in cultured rat pancreatic islets exposed to human interleukin-1 beta. (1989) (9)
Anti-IL-1alpha autoantibodies in early rheumatoid arthritis. (2001) (9)
Naturally occurring autoantibodies to interleukin-1 alpha, interleukin-6, interleukin-10, and interferon-alpha. (1994) (9)
Affinity chromatography. A new technique for partial purification of human leucocyte migration inhibitory factor. (1976) (9)
Cytokine‐induced histamine release from basophils of AIDS patients (1991) (9)
Cultures of human colonic epithelial cells isolated from endoscopical biopsies from patients with inflammatory bowel disease. Effect of IFNgamma, TNFalpha and IL-1beta on viability, butyrate oxidation and IL-8 secretion. (2000) (9)
Liposome-mediated transfer of IL-1 receptor antagonist gene to dispersed islet cells does not prevent recurrence of disease in syngeneically transplanted NOD mice. (2000) (8)
Preventive and curative effects of cyclophosphamide in an animal model of Guillain Barrè syndrome (2008) (8)
Autoantibodies to IL-1 alpha in sera from umbilical cords, children, and adults, and from patients with juvenile chronic arthritis. (1996) (8)
Sodium fusidate in steroid resistant relapses of multiple sclerosis. (1999) (8)
Maturation of human dendritic cells by monocyte-conditioned medium is dependent upon trace amounts of lipopolysaccharide inducing tumour necrosis factor alpha. (2003) (8)
Interleukin-6 (IL-6) autoantibodies and blood IL-6 measurements. (1995) (8)
Biomolecular regulation of the IgE immune response. II. In vitro IgE synthesis and spontaneous production of cytokines. (1995) (8)
Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans. (1994) (8)
Interleukin 1, but not Interleukin 1 Inhibitor, is Released from Human Monocytes by Immune Complexes (1990) (8)
Effect of melatonin on human nighttime endotoxaemia: randomized, double-blinded, cross-over study. (2014) (8)
Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. (2000) (8)
Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti‐TNF Biopharmaceuticals and Anti‐Drug Antibodies (2011) (8)
Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat (2001) (8)
Biological Properties of Lymphokines (1978) (8)
Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis. (2001) (8)
Leucocyte migration inhibitory activity of concanavalin-A-stimulated lymphocytes. In vivo and in vitro modifications with dipyridamole and acetylsalicylic acid. (2009) (8)
Influence of protease on inhibitory and stimulatory effects of interleukin 1 beta on beta-cell function. (1991) (8)
94 Treatment of Secondary Infliximab Failure in Crohn's Disease Based on Serum Levels of Infliximab and Antibodies Against Infliximab: The Danish Study of Optimizing Infliximab Therapy in Crohn's Disease (Do It Crohn) Randomized Clinical Trial (2013) (7)
Quantitation and biological activities of native tumour necrosis factor from LPS‐stimulated human monocytes (1990) (7)
Human monocyte elastolytic activity, the propeptides of types I and III procollagen, proteoglycans, and interleukin-6 in synovial fluid from patients with arthritis. (1991) (7)
Nephrotoxicity of Cyclosporin A in Patients with Newly Diagnosed Type 1 Diabetes Mellitus (1990) (7)
Interleukins increase surface ganglioside expression of pancreatic islet cells in vitro (1992) (7)
Infusion of hypertonic saline before elective hysterectomy: effects on cytokines and stress hormones. (2008) (7)
EGNA-specific LIF production of human lymphocyte subsets. (1984) (7)
Interleukin-6 is not a second mediator of interleukin-1 induced suppression of thyroid function in cultured human thyrocytes. (2009) (7)
Cytokine responses in infants infected with respiratory syncytial virus (2012) (7)
Patient-specific cell-mediated immunity against human acoustic neuroma extract. (1982) (7)
Production of interleukin (IL)-1beta, IL-1 receptor antagonist and IL-10 by blood mononuclear cells in chronic arthritis. (2000) (7)
Chronic fatigue syndrome--a controlled cross sectional study. (1994) (7)
SCLEROSING PERITONITIS AND PRACTOLOL (1975) (7)
Blood levels of CD11bH+ memory T lymphocytes are selectively upregulated in patients with active rheumatoid arthritis (1999) (7)
Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. (1997) (7)
Cytokines and soluble tumour necrosis factor I receptor levels during pretransplant conditioning in allogeneic stem-cell transplantation. (2005) (7)
Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera. (1990) (7)
Measurement of human IL-1 by LIF induction, pancreatic islet-cell cytotoxicity, and bone resorption. (1986) (6)
Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. (2003) (6)
Why is too little TNF bad? (1991) (6)
Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial (2005) (6)
Human urine deoxyribonuclease increases endogenous thymidine in the mouse thymocyte interleukin 1 assay: an artificial interleukin-1 inhibitor. (1989) (6)
Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors’ reply (2011) (6)
Production of human leukocyte migration inhibitory factor (LIF) by lymphocytes stimulated with phytohemagglutinin. II. Effects of cyclic nucleotides. (1981) (6)
Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. II. Further studies of the monocyte - T cell interactions leading to lymphokine production. (1983) (6)
Blood mononuclear cells in patients with primary Sjögren's syndrome: production of interleukins, enumeration of interleukin-2 receptors, and DNA synthesis. (1986) (5)
Can Measurements of Anti-Infliximab Antibodies Predict Acute Severe Infusion Reactions to Infliximab? (2011) (5)
Inhibition of LPS and Plasmodium falciparum Induced Cytokine Secretion by Pentoxifylline and Two Analogues (1997) (5)
Decreased plasma levels of factor II+VII+X correlate with increased levels of soluble cytokine receptors in patients with malaria and meningococcal infections (1997) (5)
Differential effects of interleukin 1 alpha and 1 beta on cultured human and rat thyroid epithelial cells. (1990) (5)
The antimalarial drug, Ro 42-1611 (arteflene), does not affect cytoadherence and cytokine-inducing properties of Plasmodium falciparum malaria parasites. (1995) (5)
Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease (2020) (5)
Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke (2019) (5)
Natural and therapy-induced antibodies to cytokines. (2004) (5)
IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a. (2002) (5)
[Chemokines and HIV infection]. (1997) (5)
Abnormal vitamin D 3 metabolism in patients with primary Sjogren ' s syndrome (5)
Comment on ‘Predicting the response to infliximab from trough serum levels’ (2010) (5)
Use of benzoyl-L-phenylalanyl-L-valyl-L-arginine (3H) methyl ester as a sensitive and selective substrate for the human lymphokine, leukocyte migration inhibitory factor (LIF). (1980) (5)
Pathogenic role of interleukin 1 and tumor necrosis factor in autoimmune endocrine diseases (1988) (5)
Partial purification of human leucocyte migration inhibitory factor (LIF) by immunosorption of supernatant protein contaminants detected by crossed immunoelectrophorsis. (1976) (5)
Plasma TNF binding capacity in patients with juvenile idiopathic arthritis. (2005) (5)
Immunological studies in thymectomized and non-thymectomized patients with myasthenia gravis. (1978) (5)
Effects of Leukotrienes on Neutrophil Migration, and on Production and Action of Lymphokines (1984) (5)
Tu1236 Comparison of Techniques for Monitoring Infliximab Bioavailability and Immunogenicity in Crohn's Disease (2012) (5)
Elastolytic activity of human monocytes from synovial fluid and blood of patients with arthritis. Relations to levels of interleukin 6 and soluble interleukin 2 receptor. (1991) (4)
Cytokine production in NOD mice on prophylactic insulin therapy (1999) (4)
Nitric oxide production is not involved in the effects of interleukin-1 beta on cAMP, thyroglobulin and interleukin-6 in TSH-stimulated human thyroid cells. (1994) (4)
Interleukin-1α: A paracrine mediator of human term labour? (1994) (4)
A matrix of cholesterol crystals, but not cholesterol alone, primes human monocytes/macrophages for excessive endotoxin-induced production of tumor necrosis factor-alpha. Role in atherosclerotic inflammation? (2014) (4)
Lymphocyte function and chromosome aberrations in patients with early mycosis fungoides and parapsoriasis en plaques. (1983) (4)
Native inhibitors (autoantibodies) of IL-1 alpha and TNF. (1989) (4)
Tumor necrosis factor-beta in human pregnancy and labor. (1997) (4)
Natural And Induced Anticytokine Antibodies In Humans (2000) (4)
Optimisation of the CT h4S bioassay for detection of human interleukin-4 secreted by mononuclear cells stimulated by phytohaemaglutinin or by human leukocyte antigen mismatched mixed lymphocyte culture. (2002) (4)
[The immune system and inflammatory diseases]. (2008) (4)
Effect of human leucocyte migration inhibitory factor (LIF) on 3', 5'-cyclic AMP levels of peripheral blood leucocytes. (2009) (4)
Role of monocytes/macrophages and interleukin 1 in antigen-induced human lymphokine production. (1984) (4)
BglII polymorphism in the human interleukin 6 (IL 6) gene. (1989) (4)
[Rituximab (MabThera) as treatment of active rheumatoid arthritis]. (2006) (4)
Blood levels of CD11b+ memory T lymphocytes are selectively upregulated in patients with active rheumatoid arthritis. (1999) (4)
In vitro modulation of human leucocyte migration and migration inhibitory factor (LIF) activity by cyclic 3',5'-AMP and cyclic 3',5'-GMP. (2009) (4)
Studies on the active site of human leukocytic pyrogen (1982) (4)
Interleukin 1‐Induced Down‐Regulation of Antibody Binding to CD4 Molecules on Human Lymphocytes (1988) (4)
Ciclosporin Treatment of Autoimmune Inflammatory Disorders of the Eye (1985) (4)
Inflammatory, non-antibody lymphocytic mediators (lymphokines). (1980) (3)
Lymphokines and soluble interleukin-2 receptors in juvenile chronic arthritis (1992) (3)
Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? (2017) (3)
[Extraintestinal manifestations in inflammatory bowel disease]. (2009) (3)
[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]. (2007) (3)
ROLE OF 1,25-DIHYDROXYVITAMIN D3 (l,25(OH)2D3) AS MODULATOR OF IMMUNOINFLAMMATORY REACTIONS (1991) (3)
Monitoring immunogenicity of protein-based TNF antagonists (2015) (3)
INTERLEUKIN 6: A FUNCTIONAL AND CELLS FROM ISLETS OF LANGERHANS STRUCTURAL IN VZTRO MODULATOR OF BETA- (1990) (3)
Modulation of human leucocyte migration inhibitory factor (LIF) by 3',5'-cyclic AMP, 3',5'-cyclic GMP and agents known to influence intracellular cyclic nucleotide metabolism. (2009) (3)
P536 Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease (2014) (3)
Determination of the human lymphokine leukocyte migration inhibitory factor (LIF) by a sensitive radioenzymatic assay. Inhibitory effect of cGMP on the esterolytic activity of highly purified LIF. (1979) (3)
Antibodies Against “Human” Biopharmaceuticals: Individualized Therapy with TNF-alpha Inhibitors Guided by Immunopharmacologic Assessments (2014) (3)
Cytokines modulate IgE-mediated histamine liberation from human basophils (1992) (3)
The treatment of presumed non‐infective uveitis with Ciclosporin A (1985) (3)
Cytokine-induced release of histamine from basophil leukocytes from AIDS patients (1990) (3)
Human leukocyte migration inhibitory factor (LIF). I. Effect of synthetic and naturally occurring esterase and protease inhibitors. (1977) (3)
Effects of prolonged exposure in vitro to interferon-gamma and tumour necrosis factor-alpha on nitric oxide and insulin production of rat pancreatic islets. (1995) (3)
[Ampicillin induced bacteriuria in children]. (1973) (2)
Substrate Specificity of the Human Lymphokine Leucocyte Migration‐Inhibitory Factor (LIF): Radioenzymic Assay and Inhibition by cGMP (1979) (2)
Regulation during Inflammation. Modulation by autoantibodies and fever (1992) (2)
Possible correlation of TNF alpha-production with -RFLP in humans. (1989) (2)
Effects of Cyclic GMP‐Agonists on Ciclosporin‐Induced Suppression of Human Lymphokine Production (1985) (2)
Sa1236 Antibodies Against Infliximab Are Associated With Increased Risk of Anti-Adalimumab Antibody Development in Patients With Inflammatory Bowel Disease (2014) (2)
A1174 IMMUNOLOGICAL AND HORMONAL RESPONSES TO LUNG SURGERY DURING ONE-LUNG VENTILATION (1990) (2)
Decreased short-term production of tumor necrosis factor-alpha and interleukin-1beta in human immunodeficiency virus-seropositive subjects. (1997) (2)
W1270 Discriminating Between Response Types in Infliximab-Treated Patients With Crohn's Disease: Sensitivity and Specificity of Combined Assessment of Infliximab Trough Levels and Anti-Drug Antibodies (2010) (2)
Case Study: Immunogenicity of Interferon-Beta (2008) (2)
Tu1142 Secondary Infliximab Treatment Failure in Crohn's Disease: Therapeutic Implications of Measuring Drug and Anti-Drug Antibodies by Three Different Binding Assays (2013) (2)
P374 Secondary infliximab treatment failure in Crohn's disease: therapeutic implications of measuring drug and anti-drug antibodies by three different binding assays (2013) (2)
Eosinophil cationic protein and eosinophil protein X: human amniotic fluid concentrations and gestational tissue content at term. (1998) (2)
[The role of cell adhesion molecules in inflammatory bowel disease and colorectal cancer]. (1997) (2)
[Cyclosporin A. A different immunosuppressive agent]. (1983) (2)
Tissue culture supernatants from human islets of Langerhans activate the oxidative burst response of human monocytes in vitro. (1995) (2)
[Danger signals and inflammasomes in autoinflammatory and autoimmune diseases]. (2011) (2)
An Unusual Case of Multiple Malignancy in an Adult (1984) (2)
[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors]. (2010) (2)
CYTOKINES IN PLASMA AND ULTRAFILTRATE IN RELATION TO HEMOFILTRATION (1991) (2)
40 – CYTOKINE ANTIBODIES (2007) (1)
Lack of Evidence for Human Lymphokines with Thrombocyte Aggregating Activity (1984) (1)
Comparison of Techniques for Monitoring Infliximab and Antibodies to Infliximab in Crohnʼs Disease Patients with Infliximab Treatment Failure: 1546 (2012) (1)
Low prevalence of antibodies and other plasma factors binding to CC chemokines and IL‐2 in HIV‐positive patients (2000) (1)
[Gingival hyperplasia due to treatment with cyclosporin (cyclosporin A)]. (1984) (1)
Necrotic ulceration of the nose in a patient with primary immunodeficiency syndrome characterized by severe defects in the production of cytokines. (1993) (1)
Interleukin‐6 (IL‐6) is not removed from plasma during experimental haemofiltration (1998) (1)
P558 Antibodies against infliximab are associated with increased risk of anti-adalimumab antibody development in patients with inflammatory bowel disease (2014) (1)
Anti-TNF-α Therapy for Extraintestinal Manifestations of Inflammatory Bowel Disease (2015) (1)
Morphological effects of sodium fusidate (fusidin) on pancreatic islet cells: an electron microscopic study. (1994) (1)
[Immunosuppression with cyclosporin induces clinical remission and improved beta cell function in patients with newly diagnosed insulin-dependent diabetes. A national and international multicenter study]. (1990) (1)
A role of immunoinflammatory hormones (cytokines) in insulin dependent diabetes mellitus? (1990) (1)
The Influence of Interleukin-1 on The Function of Human Thyroid Cells (1987) (1)
[Leukocyte migration inhibitory factor (LIF). From biological test to biochemical characterization of this lymphokine]. (1979) (1)
[Biopharmaceuticals in the treatment of rheumatoid arthritis]. (2008) (1)
[Autoinflammatory disease: a new concept]. (2002) (1)
[Innate immunity, autoimmunity and autoinflammation]. (2011) (1)
Neutralising antibodies against interferon beta in multiple sclerosis (2004) (1)
No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms: A prospective Study (2015) (1)
Immunohistology of Skin from AIDS Patients (1991) (1)
Induction of Antigen‐Specific Immunological Unresponsiveness by Inhibitors of Human Lymphocyte‐Activating Factor (1981) (1)
[Problems with clinical use of recombinant proteins]. (2003) (1)
Diagnosis of Hodgkin's disease hampered by an Epstein-Barr virus infection treated with acyclovir. (2009) (1)
Modulation of Inflammatory Cytokines by a Receptor Antagonist, Autoantibodies, and Fever (1993) (1)
[Apoptosis--programmed cell death]. (1999) (1)
Prevention and Treatment of Lethal Murine Endotoxemia by the Novel Immunomodulatory Agent MFP-14 (2001) (1)
Inhibitor of interleukin-1α and interleukin-1β-induced T-cell activation in serum of patients with active Crohn's disease (1991) (1)
[Adalimumab in the treatment of rheumatoid arthritis]. (2004) (1)
Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Experimental cytokine modulation therapy of inflammatory bowel disease (Crohn's disease and ulcerative colitis) (1996) (1)
[Immunogenicity of biopharmaceuticals. Experiences with beta-interferon, EPO and anti-TNF]. (2003) (1)
Inhibitor of interleukin-1 alpha and interleukin-1 beta-induced T-cell activation in serum of patients with active Crohn's disease. (1991) (1)
Lymphokines That Affect the Migration of Polymorphonuclear Leukocytes (1981) (1)
Antibodies to interleukin-6 in sera from normal individuals and patients with immunoinflammatory disorders (1991) (0)
Corrigendum (2008) (0)
Human somatotrophic (GH) adenoma cells interleukin (IL)-1 β induces production of il-6 and il-8. (2007) (0)
P643 Therapeutic thresholds for infliximab trough levels during maintenance treatment in patients with inflammatory bowel disease. (2017) (0)
The Role of Immune Complexes Consisting of Myelin Basic Protein (MBP), Anti‐MBP Antibodies and Complement in Promoting CD4+ T‐cell Responses to MBP in Health and Multiple Sclerosis (2004) (0)
Increased Concentrations ofInterleukin-6 andInterleukin-1 Receptor Antagonist andDecreased Concentrations ofBeta-2-Glycoprotein I inGambianChildren withCerebral Malaria (1994) (0)
Three suggestions for involvement of immunoinflammatory peptides (cytokines) in the pathogenesis of multiple sclerosis (1992) (0)
Interleukin 10 Induces the Maturation of Putative Tolerogenic Monocyte-derived Dendritic Cells as Revealed by GeneArray Analysis (2005) (0)
Abnormal vitamin D3metabolism inpatients with primary Sjogren's syndrome (1990) (0)
[Sclersong peritonitis during practolol (Eraldine) therapy]. (1975) (0)
[DNA microchips: after a revolution in biotechnology with great clinical and scientific possibilities]. (1998) (0)
Interleukin 6: A Pathogenic Factor in Autoimmune Thyroid Diseases? (1991) (0)
Clinical significance of antibodies to interferon beta therapy in patients with relapsing–remitting multiple sclerosis (2009) (0)
Monitoring Patients Treated with Type1 Interferons: Potential Reporter Genes in Patient Leucocytes (2004) (0)
Therapy-induced antibodies against interferon-β-1a and interferon-β-1b in patients with multiple sclerosis (2001) (0)
[New biological drugs for the treatment of chronic inflammatory diseases]. (2008) (0)
P584 A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease? (2017) (0)
742 DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE IN SUSTAINED, COMPLETE CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL (2021) (0)
Effects ofsodiumfusidate inanimal modelsofinsulin-dependent diabetes mellitus andseptic shock (1995) (0)
Regulation of the Immune Response (1983) (0)
Inhibition of human leukocyte migration inhibitory factor (LIF) by alpha-L-fucose. (1975) (0)
DRUG EFFECTS ON HUMAN LEUCOCYTE MIGRATION AND MIGRATION INHIBITORY ACTIVITY FROM LYMPHOCYTES STIMULATED WITH CONCANAVALIN A (2009) (0)
[Cell-mediated hypersensitivity and lymphokines]. (1976) (0)
[Molecular biology and inflammation]. (1995) (0)
Fusidin down-regulates the production of IL-6 in septic patients: a pilot study (2000) (0)
Sa1786 - Plasma Cytokine Profiles in IBD Primary Non-Responders Versus Responders to Infliximab (2018) (0)
Selected abstracts from allergy (2004) (0)
Biochemical characterization of the human lymphokine leukocyte migration inhibitory factor (LIF): role of cGMP as a specific inhibitor of the LIF esterase activity. (1979) (0)
[Molecular biology and rheumatology]. (1995) (0)
[Fever and acute phase reaction as a link in the cytokine-mediated cellular language]. (1991) (0)
Sa1268 Individualized Therapy Is Long-Term Cost-Effective Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab (2015) (0)
[The tower of Babel of terminology concerning lymphokines and interleukins (cytokines)]. (1989) (0)
Interleukin 1β - an unstable monomer (1991) (0)
Interleukin 6 is a modulator of beta-cell function (1990) (0)
Demonstration of myelin basic protein-reactive antibodies in healthy individuals and patients with multiple sclerosis using a novel highly sensitive assay (2009) (0)
Modulation of IgE-mediated basophil histamine release by various cytokines. (1992) (0)
[Toll-like receptors. What can we learn about the immune system from banana flies and a mouse strain]. (2001) (0)
Immunogenicitet af biologiske laegemidler. Erfaringer med betainterferon, EPO og anti-TNF (2003) (0)
FRI0031 Naturally occurring antibodies against different IFN-alpha subtypes are observed in some SLE patients, and may impact the IFN gene signature and disease activity (2013) (0)
Failure to detect cytokines in CSF of patients with optic neuritis and multiple sclerosis (1991) (0)
Interleukin-6 is an endogenous modulator of b-cell structure and function (1989) (0)
Selected abstracts from allergy (2004) (0)
Are microbiomes involved in paroxysmal atrial fibrillation?  Repeated clinical improvement after pivmecillinam (amdinocillin) therapy (2021) (0)
[Biological drugs in the treatment of immunoinflammatory diseases]. (2008) (0)
Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke (2019) (0)
Increase in myocardial capillary permeability by tumor necrosis factor alpha (TNF) (1992) (0)
Monitoring Patients Treated with Type 1 Interferons: Antiviral versus MxA Induction Assays (2004) (0)
Gene chip analysis of gastric gene expression in gastrin-deficient mice (2001) (0)
Letter to the Editor (1999) (0)
Ciclosporin (CyA) in the Management of Polymyositis/Idiopathic Cardiomyopathy (1985) (0)
Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus (2014) (0)
12 Pre-existing IgG antibodies to the Fab region of infliximab predict efficacy and safety in IBD patients naive to anti-TNF agents (2013) (0)
Expression of an Insulin/lnterleukin-I Receptor Antagonist Hybrid Gene in Insulin-producing Cell Lines (HIT-T15 and NIT-1) Confers Resistance against Interleukin-1 -induced Nitric Oxide Production (2013) (0)
DIAGNOSIS, TREATMENT AND PREVENTION OF VASCULAR DISEASES USING IL-1alpha autoantibodies (2006) (0)
Commentary: antibodies reacting with the infliximab Fab portion – something new? Authors' reply (2013) (0)
The Effects of Interleukin-1 (cid:98) (IL-1 (cid:98) ) on Human Thyrocyte Functions Are Counteracted by the IL-1 Receptor Antagonist* (1997) (0)
[Biological response modifiers in the treatment of immunoinflammatory diseases]. (2008) (0)
Induction of antigenspecific T cell unresponsiveness by drugs known to inactivate the monokine, T cell-activating factor (TAF) (1982) (0)
Treatment of myocarditis and polymyositic heart disease guided by endomyocardial biopsy. (1989) (0)
Circulating igm antibodies against myelin basic protein in health and multiple sclerosis: A possible component in the regulation of self-reactivity? (2007) (0)
[Treatment of rheumatoid arthritis with anti-TNF antibodies]. (1995) (0)
Sa1243 Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease (2014) (0)
Polymorphonuclear degranulation complement activation and the cytokine response in lung cancer patients undergoing thoracotomy (1994) (0)
Cyklosporin a and methylprednisolone suppress antigen-induced lymphokine production at distinct sites of the macrophage-T cell cooperative processes (1982) (0)
Pathophysiological assessment--macrophages. (1983) (0)
Infusion of hypertonic saline before elective laparotomy. Effects on cytokines and hormones (2005) (0)
[The macrophage hormone interleukin 1 (IL-1) and the tumor necrosis factor. Biological and physiopathological significance]. (1987) (0)
Endotoxins Do not Mimick the Effect of Interleukin-1 in Secondary Cultures of Human Thyroid Cells (1991) (0)
of neutralizing antibodies in multiple sclerosis patients Polymorphisms of innate pattern recognition receptors , response to interferon-beta and development (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Klaus Bendtzen?

Klaus Bendtzen is affiliated with the following schools: